ORUKA THERAPEUTICS INC (ORKA) Stock Price, Forecast & Analysis
USA - NASDAQ:ORKA - US6876041087 - Common Stock
ORKA Key Statistics, Chart & Performance
The current stock price of ORKA is 27.08 USD. In the past month the price decreased by -1.46%. In the past year, price increased by 12.65%.
ORKA Latest News, Press Relases and Analysis
ORKA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About ORKA
Company Profile
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Company Info
ORUKA THERAPEUTICS INC
855 Oak Grove Ave., Suite 100
Menlo Park CALIFORNIA US
Employees: 28
Phone: 16506067910
ORUKA THERAPEUTICS INC / ORKA FAQ
What does ORKA do?
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
What is the stock price of ORUKA THERAPEUTICS INC today?
The current stock price of ORKA is 27.08 USD. The price increased by 2.65% in the last trading session.
Does ORKA stock pay dividends?
ORKA does not pay a dividend.
What is the ChartMill rating of ORUKA THERAPEUTICS INC stock?
ORKA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for ORKA stock?
18 analysts have analysed ORKA and the average price target is 43.86 USD. This implies a price increase of 61.96% is expected in the next year compared to the current price of 27.08.
Can you provide the PE ratio for ORKA stock?
ORUKA THERAPEUTICS INC (ORKA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
ORKA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ORKA. When comparing the yearly performance of all stocks, ORKA is one of the better performing stocks in the market, outperforming 92.11% of all stocks.
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. No worries on liquidiy or solvency for ORKA as it has an excellent financial health rating, but there are worries on the profitability.
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 55.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.97% | ||
| ROE | -29.09% | ||
| Debt/Equity | 0 |
ORKA Forecast & Estimates
18 analysts have analysed ORKA and the average price target is 43.86 USD. This implies a price increase of 61.96% is expected in the next year compared to the current price of 27.08.